JP2022546807A - 癌の治療 - Google Patents

癌の治療 Download PDF

Info

Publication number
JP2022546807A
JP2022546807A JP2022513249A JP2022513249A JP2022546807A JP 2022546807 A JP2022546807 A JP 2022546807A JP 2022513249 A JP2022513249 A JP 2022513249A JP 2022513249 A JP2022513249 A JP 2022513249A JP 2022546807 A JP2022546807 A JP 2022546807A
Authority
JP
Japan
Prior art keywords
compound
cancer
independently
group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022513249A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022546807A5 (enExample
Inventor
クリストフ ディメイソン，
クリストファー スミス，
フランセスカ メルクリ，
トビアス ボールド，
マイケル ベッテス，
Original Assignee
アクセリア オンコロジー ピーティーワイ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019903263A external-priority patent/AU2019903263A0/en
Application filed by アクセリア オンコロジー ピーティーワイ リミテッド filed Critical アクセリア オンコロジー ピーティーワイ リミテッド
Publication of JP2022546807A publication Critical patent/JP2022546807A/ja
Publication of JP2022546807A5 publication Critical patent/JP2022546807A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2022513249A 2019-09-04 2020-09-04 癌の治療 Pending JP2022546807A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2019903263 2019-09-04
AU2019903263A AU2019903263A0 (en) 2019-09-04 Cancer treatment
AU2019904863 2019-12-20
AU2019904863A AU2019904863A0 (en) 2019-12-20 Cancer treatment (2)
PCT/AU2020/050936 WO2021042174A1 (en) 2019-09-04 2020-09-04 Cancer treatment

Publications (2)

Publication Number Publication Date
JP2022546807A true JP2022546807A (ja) 2022-11-09
JP2022546807A5 JP2022546807A5 (enExample) 2023-09-11

Family

ID=74851931

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022513249A Pending JP2022546807A (ja) 2019-09-04 2020-09-04 癌の治療

Country Status (5)

Country Link
US (1) US20220347146A1 (enExample)
EP (1) EP4025203A4 (enExample)
JP (1) JP2022546807A (enExample)
AU (1) AU2020343725A1 (enExample)
WO (1) WO2021042174A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2618842B1 (en) 2010-09-22 2019-04-24 Ena Therapeutics Pty Ltd Novel immunostimulatory method
AU2018391325B2 (en) 2017-12-21 2024-07-11 Axelia Oncology Pty Ltd Optimised compounds
MX2021015961A (es) 2019-06-26 2022-03-22 Ena Respiratory Pty Ltd Moleculas novedosas.

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008529978A (ja) * 2005-02-08 2008-08-07 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ 免疫原性分子
JP2012526092A (ja) * 2009-05-08 2012-10-25 サイオクサス セラピューティクス リミティド 多価アジュバントディスプレイ
JP2013537892A (ja) * 2010-09-22 2013-10-07 ザ ユニバーシティー オブ メルボルン 新規な免疫賦活法
JP2014528955A (ja) * 2011-10-06 2014-10-30 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． Ｔｌｒ２を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用
WO2016037240A1 (en) * 2014-09-12 2016-03-17 The University Of Melbourne Immunological reagent
WO2018176099A1 (en) * 2017-03-31 2018-10-04 Ena Therapeutics Pty Ltd Treatment of respiratory infection with a tlr2 agonist

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3328418A1 (en) * 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
AU2018391325B2 (en) * 2017-12-21 2024-07-11 Axelia Oncology Pty Ltd Optimised compounds
AU2020340468A1 (en) * 2019-09-04 2022-03-24 Axelia Oncology Pty Ltd Cancer immunotherapy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008529978A (ja) * 2005-02-08 2008-08-07 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ 免疫原性分子
JP2012526092A (ja) * 2009-05-08 2012-10-25 サイオクサス セラピューティクス リミティド 多価アジュバントディスプレイ
JP2013537892A (ja) * 2010-09-22 2013-10-07 ザ ユニバーシティー オブ メルボルン 新規な免疫賦活法
JP2014528955A (ja) * 2011-10-06 2014-10-30 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． Ｔｌｒ２を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用
WO2016037240A1 (en) * 2014-09-12 2016-03-17 The University Of Melbourne Immunological reagent
WO2018176099A1 (en) * 2017-03-31 2018-10-04 Ena Therapeutics Pty Ltd Treatment of respiratory infection with a tlr2 agonist

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"PEGylation of a TLR2-agonist-based vaccine delivery system improves antigen trafficking and the magn", BIOMATERIALS, vol. 137, JPN6024036276, 2017, pages 61 - 72, ISSN: 0005759781 *
"Synthesis and Evaluation of Novel TLR2 Agonists as Potential Adjuvants for Cancer Vaccines", J. MED. CHEM., vol. 63, JPN6025008705, 16 August 2019 (2019-08-16), pages 2282 - 2291, ISSN: 0005759782 *

Also Published As

Publication number Publication date
EP4025203A1 (en) 2022-07-13
US20220347146A1 (en) 2022-11-03
WO2021042174A1 (en) 2021-03-11
AU2020343725A1 (en) 2022-03-24
EP4025203A4 (en) 2023-12-20

Similar Documents

Publication Publication Date Title
US12110295B2 (en) WD40 repeat domain protein 5 (WDR5) degradation/disruption compounds and methods of use
JP7358342B2 (ja) 新規なグルタミンアンタゴニストおよびそれらの使用
JP2022546807A (ja) 癌の治療
JP2025148436A (ja) 癌免疫療法
BR112014010708B1 (pt) compostos, processo para a preparação de um composto, usos de um composto e medicamento compreendendo um composto
JP2025108536A (ja) 新規な分子
US20240316224A1 (en) Carbonic anhydrase ix targeting agents and methods
US11524082B2 (en) FBSA-based therapeutic and radioimaging conjugates targeting carbonic anhydrase positive cancers
US10857234B2 (en) Carbonic anhydrase IX inhibitor conjugates and uses thereof
JP2024036660A (ja) ホウ素中性子捕捉療法用の腫瘍組織を短時間で選択的ないし局所的に標的化できる集積性ボロン１０薬剤
US20230372551A1 (en) Radiolabeled ligands for targeted pet/spect imaging and methods of their use
TW202416974A (zh) 標靶細胞外HSP90(eHSP90)之放射性藥物及其用途
US20240252693A1 (en) Folate receptor-targeted radiotherapeutic agents and their use
US11110098B2 (en) Methods and medicaments for the treatment of renal cell carcinoma
TW202114981A (zh) Trpv1激動劑及其製備方法和用途
US20260007758A1 (en) Somatostatin subtype-2 receptor (sst2r) non-peptide drug conjugates and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250910

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260227

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260407